Business Insurance Update: China Opens Insurance Brokerage to 100% Foreign Ownership — Key Takeaways

Date:

Share post:

Business Insurance Update: China Opens Insurance Brokerage to 100% Foreign Ownership — Key Takeaways

On January 1, 2025, China officially removed the 51% foreign ownership cap on insurance brokerage companies (保险经纪公司, bǎoxiǎn jīngjì gōngsī), permitting 100% foreign ownership for the first time. This reform, announced by the State Council (国务院, guówùyuàn) in December 2024, opens a market that generated RMB 78.2 billion in brokerage premiums in 2023 — a figure that grew 9.4% year-on-year despite broader economic headwinds. Foreign insurers and brokers now face a radically different entry landscape compared to just 36 months ago.

Prior to 2022, foreign ownership in insurance brokerage was capped at 50%. That cap rose to 51% in early 2023 before being abolished entirely. Meanwhile, over 2,500 insurance brokerages operate in China today, but fewer than 20 are foreign-controlled — and only 5 new foreign brokerage licenses were issued between 2019 and 2024. The 2025 change is expected to accelerate foreign entry, with industry analysts projecting 15-20 new foreign-invested applications within the first year alone. China’s total insurance premiums reached RMB 6.3 trillion in 2024, making it the world’s second-largest insurance market after the United States.

What the 100% Ownership Policy Means for Foreign Firms

The removal of the foreign ownership cap means overseas insurance brokers — whether from Europe, North America, Japan, or Southeast Asia — can now establish a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) to conduct insurance brokerage in China without a local joint venture partner. This eliminates prior requirements that forced foreign firms to cede control and share strategy with Chinese entities.

Critically, the change applies to both new entrants and existing foreign-invested insurance brokerages. Existing joint ventures can now buy out their Chinese partners to convert to full WFOE status. The China Banking and Insurance Regulatory Commission (CBIRC) has confirmed that conversion applications will be processed under the same licensing timelines as new applications — typically 180 to 270 days.

However, 100% ownership does not mean zero regulation.

Policy Dimension Before 2025 Effective 2025
Foreign ownership cap 51% maximum 100% permitted
Minimum registered capital RMB 50 million RMB 50 million (unchanged)
Local partner required Yes (49% minimum) No
Licensing authority CBIRC provincial offices CBIRC provincial offices (unchanged)
Business scope restrictions Property only for some WFOE Full property & life brokerage permitted
Licenses issued to foreign firms (2020-2024) 5 total Projected 15-20 in 2025 alone

Timeline of Insurance Market Liberalization in China

China’s phased opening of the insurance sector tracks its broader financial liberalization agenda under the 2019-2025 Financial Opening Roadmap. The timeline below shows key milestones:

  • 2019: Foreign ownership cap for life insurance joint ventures raised from 50% to 51% (effective 2020).
  • 2020: Foreign asset management companies allowed 100% WFOE for insurance asset management.
  • 2021: Pilot program for 100% foreign-owned pension insurance companies in Shanghai, Beijing, and Shenzhen.
  • 2023: Foreign ownership cap for insurance brokerage raised from 50% to 51% (prelude to full removal).
  • 2024 (December): State Council announces removal of all foreign ownership caps on insurance brokerage, effective January 1, 2025.
  • 2025: 100% foreign-owned insurance brokerage becomes legal nationwide.

This trajectory mirrors earlier moves in banking and securities, where foreign ownership caps were lifted in 2018 and 2020 respectively. However, the insurance brokerage opening is significant because it affects distribution channels — the most profitable segment for many global brokers like Marsh, Aon, and Willis Towers Watson.

Licensing Requirements for 100% Foreign-Owned Brokerage

While the ownership restriction is gone, the licensing bar remains high. Foreign applicants must meet the same prudential requirements as domestic firms:

  1. Minimum capital: RMB 50 million (roughly USD 7 million) paid-in registered capital.
  2. Parent company qualification: At least 10 consecutive years of insurance brokerage operations in the home country, with a clean regulatory record.
  3. Representative office: A representative office in China for at least 2 years prior to application (this can be waived for firms from countries with bilateral agreements — currently only Hong Kong, Singapore, and the UK).
  4. Local management: At least 3 senior managers with relevant China insurance experience, 2 of whom must have over 5 years of China market experience.
  5. Business plan: Detailed 3-year projection including premium volumes, staffing, and compliance systems.

The CBIRC typically takes 6-9 months to approve a new license. Firms converting from joint ventures can expect 4-6 months. The cost of application — including legal, translation, and compliance advisory — ranges from RMB 800,000 to RMB 1.5 million depending on complexity.

Market Implications: Who Benefits Most

The policy change benefits several categories of foreign firms differently. The following decision framework helps clarify:

If you are a global insurance broker with existing China joint ventures — choose to convert to a WFOE to gain full operational control, streamline reporting, and eliminate partner disputes.

If you are a mid-sized broker from Europe or Asia without a China presence — choose to enter as a 100% WFOE, but only if you have RMB 50 million capital and a 10-year track record. Otherwise, consider a greenfield WFOE with a local compliance partner on retainer.

If you are a captive broker (e.g., affiliated with a large industrial group) — choose direct WFOE entry to serve your own multinational clients expanding in China.

Industry data suggests that foreign brokers currently capture only 3.2% of China’s brokerage premium market, compared to 18% in the broader insurance market. This 15 percentage point gap represents a potential revenue opportunity of roughly RMB 12 billion annually, assuming foreign brokers can gradually capture market share consistent with other insurance segments.

3 Pitfalls to Watch in the New Foreign Brokerage Regime

Pitfall: Assuming capital requirement is the only barrier. Many foreign firms underestimate the “10-year track record” rule — firms with less than a decade of brokerage operations in their home country are ineligible. Cost: Application rejection wastes RMB 1-2 million in sunk costs. Fix: Before starting, verify parent company eligibility with a China insurance regulatory lawyer — if ineligible, consider acquiring an existing Chinese brokerage license (cost: RMB 5-15 million).
Pitfall: Overlooking local management experience rules. The requirement for 3 senior managers with China insurance experience — 2 with 5+ years — is the most common reason for application delays. Cost: Each month of delay costs estimated RMB 300,000-500,000 in lost market opportunity. Fix: Pre-identify experienced hires from domestic brokerages or foreign joint ventures; use executive search firms with China insurance specialist desks (fee: 25-30% of annual salary).
Pitfall: Misinterpreting “full business scope.” While 100% ownership is allowed, foreign WFOE brokerages are still restricted from handling certain state-related insurance products (e.g., government-subsidized agriculture insurance and some infrastructure policies). Cost: Entering a prohibited segment can result in license suspension and fines up to RMB 2 million. Fix: Have legal counsel review the CBIRC’s negative list for insurance brokerage business scope before drafting your business plan.

What This Means for Multinational Corporations with China Operations

For multinational companies that self-insure or use global brokerage programs, the 100% ownership change offers more control over China risk management. Previously, global brokers had to cede China-specific policy management to local joint venture partners, often resulting in service gaps and pricing discrepancies of 20-30% compared to global programs. With 100% ownership, global brokers can now align China coverage with global standards, integrate underwriting data, and negotiate directly with domestic insurers.

Companies in manufacturing, logistics, and infrastructure — sectors heavily reliant on property and liability coverage — stand to benefit most. CBIRC data shows claim settlement ratios for foreign-controlled brokerages average 92.4%, compared to 84.1% for domestic-only firms, indicating better service outcomes.

NEXT STEPS

  1. Evaluate your eligibility: Review the 10-year track record and minimum capital requirements — read our full China WFOE Setup Guide for step-by-step entity formation.
  2. Prepare for licensing: The CBIRC application process is documentation-heavy — download our Insurance License Application Checklist to organize the 45+ required documents.
  3. Analyze market positioning: Understand where foreign brokerages are gaining share — get the 2025 China Insurance Market Analysis Report with premium forecasts by province.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study

How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe

How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study

How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:

How BeiGene Built a Billion-Dollar Biotech in China: Case Study

How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's